INTRODUCTION
In the natural history of cirrhosis the occurrence of decompensation results in a tremendous decrease of life expectancy, from approximately 97 % to 40% at one year [1] . It is now recognized that associated conditions such as co-infection with HIV, lack of treatment response in case of viral etiology, or active alcohol drinking, may accelerate the decompensation process [2, 3] .
Metabolic syndrome (MS) is a very frequent condition in the western world. It is not a disease per se but a constellation of associated disorders that have as a central core visceral obesity and insulin resistance [4] . is entity, besides increasing the risk of cardiovascular and diabetes related death, promotes the development of non-alcoholic fatty liver disease which may progress to end-stage liver disease. Moreover, the progression of chronic liver diseases, in terms of brosis progression or lack of treatment response proved to be negatively in uenced by the co-existence of the MS and its components [5] [6] .
Recently, it was demonstrated that overweight and obesity favors the occurrence of decompensation in patients who were previously compensated [7] [8] [9] . Additionally, it is known that insulin resistance is common among patients with cirrhosis, due to down regulation of insulin receptors and J Gastrointestin Liver Dis, December 2014 Vol. 23 No 4: 397-403 reduced insulin clearance secondary to hepatic insu ciency and porto-systemic shunting [10] . It was also demonstrated that insulin resistance is positively correlated with portal hypertension (PHT) evaluated directly by hepatic venous pressure gradient (HVPG) measurement [11] or indirectly as the presence of esophageal varices (EV) [12] . Furthermore, obesity and diabetes represent independent risk factors for development of hepatocellular carcinoma in patients with NASH [13] . However, whether the presence of MS favors clinical decompensation in patients with cirrhosis is unclear.
e aim of this study was to evaluate: a) whether the prevalence and components of the MS are di erent between patients with compensated and decompensated cirrhosis from a contemporary population and b) if the MS and its components increase the risk of decompensation and other clinical events in patients with cirrhosis.
PATIENTS AND METHODS
Between November 2006 and November 2008, 10,089 inpatients and outpatients were screened at the 3rd Medical Clinic (Cluj-Napoca, Romania) for MS (Finalism study, CEEX 94/31.07.2006). In this study, MS was de ned according to the 2004 AHA de nition [14] and the prevalence of MS in the entire population was approximately 40%.
For the present study, only patients previously diagnosed with liver cirrhosis were included. e diagnosis of cirrhosis was based on specific findings on clinical examination, laboratory and imaging, and in a minority of patients on liver biopsy. us, 704 cirrhotic patients were considered for inclusion. Among these, 303 were decompensated at inclusion or had a previous episode of decompensation. From the remaining patients, 121 were not followed-up in our clinic. e remaining 280 fully compensated patients were followed-up. ey were censored on the rst occurrence of any liver-related event (LRE) (see the de nition below) or on the last available visit on follow-up (Fig. 1) .
For the first aim of this study (transversal design), decompensated patients were compared to compensated patients regarding the prevalence of MS and its components.
For the second aim of the study (longitudinal design), only fully compensated patients followed-up at our center were considered.
Clinical and laboratory data of the followed-up patients were gathered and analyzed retrospectively from the patients' records. Plasma albumin was not readily available at the time of the study in our Center and was not included in the routine assessment of cirrhotic patients; for this reason the Child-Pugh score could not be calculated.
In order to decrease the risk of selection bias in this retrospective analysis, data from a subgroup of 156 patients with rigorous follow-up (> 2 years of follow-up and > 4 visits) were studied separately.
Clinical history, physical examination including body weight, blood tests, abdominal ultrasonography, and the analyses for MS screening were done at the inclusion in all patients.
e MS criteria were reviewed in all 704 patients and MS was rede ned according to the 2009 AHA de nition [15] as the presence of at least 3 criteria among the following: increased waist circumference (WC) (≥ 94 cm in men; ≥ 80 cm in women), elevated serum triglyceride level (≥ 150 mg/ dL), reduced HDL-cholesterol level (< 40 mg/dL in men; < 50 mg/dL in women), history of arterial hypertension, previously diagnosed diabetes, or elevated fasting glucose level (≥ 100 mg/ dL). In decompensated patients with ascites, the WC was not Liver related events were de ned as one or more of the following: clinical decompensation (ascites, variceal bleeding, hepatorenal syndrome, jaundice de ned as total bilirubin > 3mg/dL, and encephalopathy), hepatocellular carcinoma, non-tumoral portal vein thrombosis and bacterial infections.
A subanalysis restricted to PHT related events (ascites, hydrothorax, variceal bleeding) was also performed.
All patients signed a written informed consent approved by the Ethical Committee of the Cluj-Napoca Medical University at inclusion in the Finalism study and consented to the anonymous use of their data. e present study was designed respecting the ethical guidelines issued by the 2000 revision (Edinburgh) of the 1975 Declaration of Helsinki.
Statistical analysis
Data were expressed as mean ± standard deviation (SD) and qualitative variables as frequencies. e Anova or MannWhitney tests were used for quantitative variables for the comparison between groups; the chi-square and Fisher's exact tests were used for qualitative data where appropriate.
For multivariate analysis, a Cox regression using backward LR model was used in order to determine the parameters associated with liver related or PHT-related events.
Actuarial rates of complications were calculated using the Kaplan-Meier plots and were compared by the Log rank test. A p value <0.05 was considered as the level of signi cance. Statistical analysis was performed using the SPSS so ware version 20 (SPSS Inc Chicago, IL, USA).
RESULTS

Patients' characteristics
The characteristics of all patients, including those decompensated at inclusion (303) and those who were followed-up (280) are listed in Table I . In the compensated group, 155 (55%) of 223 patients had EV, and of these 54 (24%) had large EV. In this group, 117 (41%) patients were following a prophylactic treatment with non-selective beta-blockers. When the groups of decompensated and compensated patients were compared, as expected, a significant difference was found concerning the variables related to the liver function and PHT: MELD score (p<0.001), total bilirubin (p=0.03), INR (p=0.001) and platelet count (p=0.008). Also, there was a signi cant di erence between the two groups regarding the (Table I) . However, HDL-cholesterol level was lower in decompensated patients. e WC as well as BMI was not di erent.
Complications during follow-up
Two hundred eighty patients were followed-up for a mean period of 28.1 ± 18 months. During follow up, 85 patients (30%) presented with at least one LRE. Complications are presented in Table II . e most frequent complication, as expected, was ascites followed by jaundice. None of these patients died or received a transplant during the follow-up until the end point.
e proportion of LREs was also similar in the subgroup of patients with rigorous follow-up (Table II) . In this subgroup, the mean follow-up period was of 34.5 ± 18 months.
avoid colinearity with MELD score, INR and bilirubin were not included in the model. In the subgroup of 156 patients, the results were similar in the univariate and multivariate analysis.
Regarding PHT-related complications, in all the 280 patients bilirubin level, platelet count, INR, MELD scores, presence of EV and treatment with beta-blockers signi cantly correlated to this end-point. In the multivariate analysis, only MELD score (HR=1.032, p=0.04) and beta-blocker treatment (HR=0.4, p=0.03) correlated with PHT events. In the subgroup of 156 patients, the univariate analysis revealed that bilirubin, platelet count, INR, AST, MELD score, presence of MS, EV and beta-blocker treatment signi cantly correlated with the PHT events. In the multivariate analysis, beta-blocker treatment was the only variable correlated with PHT events (HR=0.35, p=0.06). Interestingly, in the last step, the variable eliminated from the model was the presence of MS, which doubled the risk of events.
Metabolic syndrome and the risk of LRE
Among all the variables included in MS de nition none was correlated with the occurrence of LRE or PHT related complications (Table III) .
Arterial hypertension and increasing BMI showed a trend to lower the risk of LREs. is trend was kept when PHT complications were analyzed and thus, the presence of MS, arterial hypertension, BMI and WC were inversely correlated with the complications' rate.
When the subgroup of 156 patients was analyzed the results obtained were similar.
e actuarial rate of remaining free of LREs according to the presence or absence of MS was 76.7% and 66.5%, respectively (Log Rank, p=0.2) (Fig. 2A) .
Concerning the PHT events, the actuarial rate of remaining free of complications according to the presence or absence of MS was 83.5% and 74.6%, respectively (Log Rank, p=0.1) (Fig. 2B) .
During the follow-up, 11 patients developed hepatocellular carcinoma in a mean interval of 23.4 ± 8.6 months. According to the presence of MS at the inclusion, there was no di erence regarding the risk of hepatocellular carcinoma (5 out of the 11 patients had MS at the inclusion, Log rank, p=0.58).
When all MS criteria were studied separately in the survival analysis, none reached the level of discrimination between patients with and without LRE or PHT related complications. (6) 12 (3)(7.7) PHT: portal hypertension; SBP: spontaneous bacterial peritonitis
Parameters associated with complications
All the clinical parameters were compared between patients with and without LRE. In the univariate analysis, the occurrence of complications was correlated with total bilirubin level, platelet count, INR, AST and MELD score. In the multivariate analysis, the only variable correlated with the end-point was MELD score (HR=1.024, p=0.03). In order to In order to see if the results are in uenced by the presence of the EV or beta-blocker treatment a subgroup analysis of patients without EV was performed. e survival without LRE and PHT related complications was still higher in patients with MS, without statistical signi cance.
DISCUSSION
e present study indicates that the presence of MS or of any of its de ning criteria is not correlated with the risk of LRE or PHT complications in the short term (2-3 years).
Even if it is not surprising that patients with decompensation at inclusion had significantly less often MS, it should be emphasized that WC and BMI were not di erent between the two groups, probably in relation with ascites, which is the most frequent decompensation event. Moreover, HDL-cholesterol levels were inversely modi ed being higher in compensated patients. In this context we may conclude that in this subgroup of patients the MS de ning criteria are not reliable enough, especially when other de nitions of MS are used having WC as a mandatory criterion.
From the best of our knowledge, this is the rst study that speci cally addresses the problem of MS in patients with cirrhosis and the risk of decompensation. Until now there were a few studies that investigated some of the MS components and the results were controversial. In a recent study, the MS proved to be more prevalent in patients with advanced HBV hepatitis and cirrhosis [16] . In a prospective cohort of 56 patients of whom 38% were diagnosed with diabetes, there was a signi cant di erence regarding 5 year survival between patients with diabetes (56.6%) and patients with normal oral glucose tolerance test (94.7%) [17] . However, those patients with impaired oral glucose tolerance test, who at least in part ful lled the MS criteria regarding glucose metabolism, did not have a di erent survival rate compared to those with a normal test. In a very recent retrospective study the presence of diabetes proved to be an independent prognostic factor regarding death and transplantation [18] , but in this cohort almost half of the patients had complications of cirrhosis, especially hepatocellular carcinoma and ascites. Diabetes only in uenced transplantation-free survival in patients with a MELD score less than 10. New onset diabetes in patients with chronic hepatitis C proved to increase the risk of cirrhosis development and decompensation [19] . However, in this retrospective study, patients with new onset diabetes at inclusion were signi cantly older, with more advanced liver disease and with more co-morbidities resulting in a possible selection bias. In our study, patients with or without diabetes had similar actuarial rates of survival without LRE, 73% vs. 69%, respectively. Metabolic syndrome proved to increase the risk of cardiovascular events, but not the overall survival and treatment response to ursodeoxycholic acid, in 171 patients with primary biliary cirrhosis followed for 137 months [20] . However, only a few patients were in the cirrhotic stage at the moment of inclusion.
Insulin resistance and increased BMI were showed to favor fibrosis progression and decompensation in the HALT-C cohort, which included patients with severe brosis or cirrhosis due to chronic HCV infection [9] . In this study, despite the high incidence of MS criteria (> 25% of the patients had TG level > 150mg/dL; almost 50% had low HDL cholesterol levels and 45% of men and 66% of women had high WC), none of the MS de ning variables were correlated with the end-point in a mean follow-up of almost 4 years.
During a longer follow-up (59 months) of a cohort of 161 perfectly compensated cirrhotic patients (HVPG >6 mmHg and no EV), overweight and obesity increased the risk of decompensation [8] . Moreover, obesity impaired the response to beta-blocker treatment, estimated as HVPG modi cation. However, in this study the analysis of the MS speci c criteria was not done.
Interestingly and somewhat surprising, we found a "protective" e ect (with signi cance trend) of the MS presence, arterial hypertension, increasing BMI and WC against LRE and PHT related complications. is e ect was maintained even a er the analysis of a subgroup of patients without EV and without beta-blocker treatment. By this subgroup analysis we discarded a hidden protective e ect of beta-blockers, known to favor development of MS and protect cirrhotic patients against PHT related complications. Nevertheless, we believe that this is a false "protective" e ect and that it is most probably related to the associated nutritional degradation and systemic vasodilatation of the patients who decompensate more rapidly. It has been already proved that poor nutritional status impairs survival in patients with cirrhosis [21, 22] .
ere are two main drawbacks of this study. One is the retrospective design and, therefore, the increased risk of selection bias. In order to overcome this inconvenience we made a subgroup analysis of patients with a more rigorous follow-up, which we arbitrarily considered in those patients who were regularly seen for more than two years. With this subgroup analysis we also attenuated the second major limitation of this study: the relatively short follow-up period. In our study, we had a relatively higher than expected prevalence of EV (55%) in the compensated subgroup and therefore, these patients had probably a more advanced disease and a higher risk to decompensate. is population structure may partially explain the "protective" e ect of MS. In order to avoid this potential bias, we performed a subgroup analysis in patients without EV and the e ect of MS was maintained. Other limitations of the study are the lack of data about alcohol abstinence for alcoholic cirrhosis patients or antiviral therapy for patients with viral etiology, a treatment that certainly in uences prognosis. More prospective and longer follow-up studies are required to better de ne the relation between MS and the risk of LREs in patients with compensated cirrhosis.
CONCLUSIONS
In the short term, the presence of metabolic syndrome or of any of its de ning criteria did not increase the risk of decompensation in our cohort of patients with cirrhosis. Most probably, the severity of liver failure and a worsening nutritional status play a more relevant role in the short-term prognosis. In the decompensated stage of cirrhosis, the metabolic syndrome de ning criteria did not contribute in any applicable way. Prospective studies with clear inclusion criteria and a longer follow-up period are required to reach a de nitive conclusion regarding this issue.
